German govt’s innovation fund must also extend to medtech
This article was originally published in Clinica
Executive Summary
€1.2bn over four years is how German parliamentary state secretary for health Annette Widmann-Mauz puts it. The G-BA (Gemeinsamer Bundesausschuss) reimbursement authority itself prefers the more straightforward €300m per year. One might sound bigger, and the incoming Union-SPD government understandably wants to drum up as much early support as possible for its planned “Innovationsfonds”. But for the medtech industry the only question is: what‘s really in it for us?
You may also be interested in...
Germany – Still Europe's Stand-Out Medtech Innovation Market
Germany's introduction of benefit assessments for class IIb and class III medical devices, and the impending EU Medical Device and IVD Regulations will place an unquantified strain on medtech manufacturers in Europe's largest market. But new innovation schemes are adding more dimensions for businesses locally.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.